Literature DB >> 12416542

Triple-dose contrast/magnetization transfer suppressed imaging of 'non-enhancing' brain gliomas.

Bradley J Erickson1, Norbert G Campeau, Shawn A Schreiner, Jan C Buckner, Brian P O'Neill, Judith R O'Fallon.   

Abstract

PURPOSE: Triple-dose (TD) gadolinium contrast administration and magnetization transfer suppression (MTS) in brain magnetic resonance imaging (MRI) have proven to be useful for demonstrating additional enhancing lesions in some diseases. The purpose of this study was to determine if there is a subset of brain tumors that demonstrate contrast enhancement with TD and MTS that do not enhance with standard imaging and standard contrast dose.
MATERIALS AND METHODS: Fifteen patients with either newly diagnosed primary brain tumor or brain tumor that had been followed for more than 2 years were enrolled. T1-weighted MTS images without IV contrast, with 0.1 mmol/kg without MTS (single-dose (SD) images), and with additional 0.2 mmol/kg gadolinium and MTS ('TD/MTS') were obtained.
RESULTS: None of the patients had enhancement on SD images. Six patients had areas of enhancement on TD/MTS images ('exact' chi-squared p = 0.017).
CONCLUSION: A statistically significant increased rate of contrast enhancement was found on TD/MTS images in patients whose tumors did not enhance at single dose without MTS. It is possible that small areas of enhancement seen only with TD/MTS might represent areas of higher-grade tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416542     DOI: 10.1023/a:1020274110502

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

1.  Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02.

Authors:  B Donahue; C B Scott; J S Nelson; M Rotman; K J Murray; D F Nelson; F L Banker; J D Earle; J A Fischbach; S O Asbell; L E Gaspar; A M Markoe; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-15       Impact factor: 7.038

2.  Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer.

Authors:  R C Mehta; G B Pike; D R Enzmann
Journal:  AJNR Am J Neuroradiol       Date:  1995-10       Impact factor: 3.825

3.  MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer.

Authors:  M Knauth; M Forsting; M Hartmann; S Heiland; T Balzer; K Sartor
Journal:  AJNR Am J Neuroradiol       Date:  1996 Nov-Dec       Impact factor: 3.825

4.  Frameless stereotactic-directed tissue sampling during surgery of suspected low-grade gliomas to avoid histological undergrading.

Authors:  K Roessler; T Czech; W Dietrich; K Ungersboeck; C Nasel; J A Hainfellner; W T Koos
Journal:  Minim Invasive Neurosurg       Date:  1998-12

5.  Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients.

Authors:  M Rovaris; R Capra; V Martinelli; C Gasperini; F Prandini; C Pozzilli; G Comi; M Filippi
Journal:  J Neurol Sci       Date:  1999-12-15       Impact factor: 3.181

6.  Comparison of single- and triple-dose contrast material in the MR screening of brain metastases.

Authors:  G Sze; C Johnson; Y Kawamura; S N Goldberg; R Lange; R J Friedland; R J Wolf
Journal:  AJNR Am J Neuroradiol       Date:  1998-05       Impact factor: 3.825

7.  The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis.

Authors:  W T Yuh; E T Tali; H D Nguyen; T M Simonson; N A Mayr; D J Fisher
Journal:  AJNR Am J Neuroradiol       Date:  1995-02       Impact factor: 3.825

8.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis.

Authors:  M Filippi; A Campi; V Martinelli; B Colombo; T Yousry; N Canal; G Scotti; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

9.  MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.

Authors:  M J Kuhn; G M Hammer; L C Swenson; H T Youssef; T J Gleason
Journal:  Comput Med Imaging Graph       Date:  1994 Sep-Oct       Impact factor: 4.790

10.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

Authors:  M Filippi; T Yousry; A Campi; C Kandziora; B Colombo; R Voltz; V Martinelli; S Spuler; S Bressi; G Scotti; G Comi
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910

  10 in total
  4 in total

Review 1.  Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.

Authors:  Hemant Sarin
Journal:  Ther Deliv       Date:  2010-08

Review 2.  Clinical experience with MultiHance in CNS imaging.

Authors:  M Essig
Journal:  Eur Radiol       Date:  2003-11       Impact factor: 5.315

3.  Effects of ionic and non-ionic paramagnetic contrast media on brain bio-electric activity.

Authors:  A Messori; G Polonara; L Regnicolo; L Provinciali; M Signorino; U Salvolini
Journal:  Neuroradiology       Date:  2005-08-25       Impact factor: 2.804

4.  Quantification of dispersion of Gd-DTPA from the initial area of enhancement into the peritumoral zone of edema in brain tumors.

Authors:  Igor N Pronin; Kathleen A McManus; Andrei I Holodny; Kyung K Peck; Valeri N Kornienko
Journal:  J Neurooncol       Date:  2009-03-29       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.